Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Christina Yap*, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R Jeffry Evans, Richard Peck, Kathryn S Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John D IsaacsRobert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S Percy Ivy, Lynley V Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J Weir

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract / Description of output

The CONSORT (CONsolidated Standards Of Reporting Trials) 2010 statement is the standard guideline for reporting completed randomised trials. The CONSORT Dose-finding Extension (DEFINE) extends the guidance (with 21 new items and 19 modified items) to early phase dose-finding trials with interim dose escalation or de-escalation strategies. Such trials generally focus on safety, tolerability, activity, and recommending dosing and scheduling regimens for further clinical development. These trials are often inadequately reported, hampering their informativeness and making evidence informed decisions difficult. The CONSORT-DEFINE guidance aims to develop an international, consensus driven guideline for reporting early phase dose-finding trials to promote transparency, completeness, reproducibility, and facilitate the interpretation of the results. The CONSORT-DEFINE guidance provides recommendations for essential items that should be reported in early phase dose-finding trials to promote greater clarity, reproducibility, informativeness, and usefulness of results.

Original languageEnglish
Article numbere076387
Number of pages14
JournalBMJ (Clinical Research ed.)
Volume383
DOIs
Publication statusPublished - 20 Oct 2023

Fingerprint

Dive into the research topics of 'Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance'. Together they form a unique fingerprint.

Cite this